参考文献/References:
[1]李汝芳,李登媛.CXCL9、CXCL10在肺动脉高压中的研究进展[J].中国呼吸与危重监护杂志,2024,23(11):818-822.
[2]RUOPP N F,COCKRILL B A.Diagnosis and treatment of pulmonary arterial hypertension:A review[J].JAMA,2022,327(14):1379-1391.
[3]陈倩冰,李逸轩,刘怡曼,等.肺动脉高压血管重塑过程中的巨噬细胞核心作用机制研究探讨[J].天津中医药,2024,41(10):1325-1334.
[4]AL-QAZAZI R,LIMA P D A,PRISCO S Z,et al.Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2022,206(5):608-624.
[5]JIANG Y,SONG S,LIU J,et al.Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension[J].Front Immunol,2023,14(1):1206452.
[6]周梦丹,李库林,王如兴.巨噬细胞焦亡促进动脉粥样硬化发生发展的作用及其机制研究进展[J].心血管病学进展,2024,45(12):1114-1117,1122.
[7]陈榕,何梓炫,颜烨,等.栀子及其主要成分的药理及毒性作用研究进展[J].中草药,2023,54(18):6092-6105.
[8]SHEN T,LEI T,CHEN L,et al.Gardenoside hinders caspase-1-mediated hepatocyte pyroptosis through the CTCF/DPP4 signaling pathway[J].Front Physiol,2021,12:669202.
[9]吴常伟,罗祠君,刘锦铭.特发性肺纤维化合并肺动脉高压的发病机制和治疗进展[J].同济大学学报(医学版),2024,45(5):649-655.
[10]LIU S F,NAMBIAR VEETIL N,LI Q,et al.Pulmonary hypertension:Linking inflammation and pulmonary arterial stiffening[J].Front Immunol,2022,13(1):959209.
[11]KLOC M,KUBIAK J Z,GHOBRIAL R M.Macrophage,dendritic,smooth muscle,endothelium,and stem cells-derived foam cells in atherosclerosis[J].Int J Mol Sci,2022,23(22):14154.
[12]KLOUDA T,YUAN K.Inflammation in pulmonary arterial hypertension[J].Adv Exp Med Biol,2021,1303:351-372.
[13]谭骏岚,易健,曹闲雅,等.基于PPAR-γ/NF-κB信号通路探讨肺心汤对野百合碱诱导肺动脉高压大鼠模型的作用及机制[J].中药新药与临床药理,2024,35(3):307-316.
[14]王琳,闫海峰,高宁,等.丹参对野百合碱诱导肺动脉高压大鼠肺动脉压及氧化应激的影响[J].现代中西医结合杂志,2023,32(10):1366-1370.
[15]LIU L,ZHANG H,TANG X,et al.Geniposide ameliorates psoriatic skin inflammation by inhibiting the TLR4/MyD88/NF-κB p65 signaling pathway and MMP9[J].Int Immunopharmacol,2024,133(1):112082.
[16]金安松,钟莲梅,徐春燕,等.栀子苷减轻乙型脑炎病毒诱导的认知功能受损及其机制探讨[J].现代免疫学,2024,44(6):500-505.
[17]马晓飞,焦彦如,张俊杰.栀子苷对肝脏缺血再灌注损伤大鼠炎症反应、氧化应激和PI3K/Akt信号通路的影响[J].现代药物与临床,2023,38(1):29-36.
[18]ZHENG Y,GAO D,XIE H,et al.Geniposidic acid inhibits OVA-induced asthma by suppressing allergic airway inflammation and regulating gut microbiota[J].Front Immunol,2025,16:1549459.
[19]李陈广,麦凤怡,梁靖蓉,等.NLRP3炎症小体抑制剂的研究进展[J].中国药理学通报,2024,40(10):1801-1808.
[20]WU J,LV T,LIU Y,et al.The role of quercetin in NLRP3-associated inflammation[J].Inflammopharmacology,2024,32(6):3585-3610.
[21]VASUDEVAN S O,BEHL B,RATHINAM V A.Pyroptosis-induced inflammation and tissue damage[J].Semin Immunol,2023,69(1):101781.
[22]李贤梅,李敏,杨振宁,等.细胞焦亡在肺部疾病中的研究进展[J].内科理论与实践,2025,20(5):420-425.
[23]OUYANG B,DENG L,YANG F,et al.Albumin-based formononetin nanomedicines for lung injury and fibrosis therapy via blocking macrophage pyroptosis[J].Mater Today Bio,2023,20:100643.
[24]LI B,LIU J,HE W,et al.Inhibition of macrophage inflammasome assembly and pyroptosis with GC-1 ameliorates acute lung injury[J].Theranostics,2025,15(6):2360-2374.
[25]JIANG Y,SU Y,LI C,et al.Geniposide alleviates post-myocardial infarction-induced pyroptosis by modulating the thioredoxin-interacting protein/NLRP3 signaling pathway[J].Cytojournal,2024,21:80.
相似文献/References:
[1]王全宏,蔡宇星△,徐 辉.心脏超声在重症监护室肺动脉高压患者肺血管压力和右心功能评估中的应用分析*[J].陕西医学杂志,2019,(7):863.
WANG Quanhong,CAI Yuxing,XU Hui..Application of echocardiography in evaluation of pulmonary vascular pressure and right heart function in patients with pulmonary hypertension in intensive care unit[J].,2019,(7):863.
[2]王 蕊,尚粉青△,叶玉兰,等.KLF2在肺动脉高压大鼠肺组织中的表达及机制探讨*[J].陕西医学杂志,2020,49(8):919.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.002]
WANG Rui,SHANG Fenqing,YE Yulan,et al.Expression of KLF2 in pulmonary tissue of rats with pulmonary hypertension and its mechanism[J].,2020,49(7):919.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.002]
[3]马威武,刘 强,李帅彪,等.栀子苷对部分膀胱出口梗阻模型大鼠膀胱功能障碍的改善作用及机制探讨[J].陕西医学杂志,2023,52(11):1478.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.006]
MA Weiwu,LIU Qiang,LI Shuaibiao,et al.Improvement effect and mechanism of geniposide on bladder dysfunction in rat model of partial bladder outlet obstruction[J].,2023,52(7):1478.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.006]
[4]赵亚男,解 琪,贾文旋,等.沙库巴曲缬沙坦联合托伐普坦治疗肺动脉高压所致右心衰竭疗效观察[J].陕西医学杂志,2024,(12):1680.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.019]
ZHAO Yanan,XIE Qi,JIA Wenxuan,et al.Efficacy of sacubitril/valsartan combined with tolvaptan in treatment of pulmonary arterial hypertension-induced right heart failure[J].,2024,(7):1680.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.019]